Newly established borderline resectable 1 (BR1) category is one of the favorable candidates for selecting the use of multidisciplinary combination therapy in patients with advanced hepatocellular carcinoma treated with systemic therapy
In patients with advanced HCC with intrahepatic target nodules the BR1 category is one of the favorable candidates for selecting those to be treated with MCT strategies.
Authors
- Takuyo Kozuka (ORCID: https://orcid.org/0000-0002-4527-2638)
- Masaru Matsumura (ORCID: https://orcid.org/0000-0001-7898-7595)
- Yasuka Eriksson
- Yusuke Kawamura (ORCID: https://orcid.org/0000-0001-6148-0042)
- Masaji Hashimoto (ORCID: https://orcid.org/0000-0003-0616-3348)
- Tetsuya Hosaka (ORCID: https://orcid.org/0000-0003-0302-2275)
- Licht Tominaga
- Norio Akuta (ORCID: https://orcid.org/0000-0001-5386-9672)
- Hitomi Sezaki (ORCID: https://orcid.org/0000-0002-4282-0934)
- Shigeki Yamamoto (ORCID: https://orcid.org/0000-0002-4937-4973)
- Satoshi Okubo (ORCID: https://orcid.org/0000-0002-4176-3851)
- Fumitaka Suzuki (ORCID: https://orcid.org/0000-0001-5232-796X)
- Yoshiyuki Suzuki (ORCID: https://orcid.org/0000-0001-9747-5552)
- Hiromitsu Kumada
- Satoshi Saitoh
- Yasuji Arase
- K Ikeda
- Junichi Shindoh
Institutions
- Toranomon Hospital (JP)
Publication Details
- Journal
- Hepatology Research
- Published
- 2024-09-26
- DOI
- https://doi.org/10.1111/hepr.14114
- Citations
- 8
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 2.96
Funders
- Ministry of Health, Labour and Welfare